Tim Allsopp
Corporate Officer/Principal at The University of Edinburgh
Profile
Tim Allsopp is currently working as the Principal at The University of Edinburgh since 1994.
Prior to this, he worked as the Chief Scientific Officer at Stem Cell Sciences Plc, Principal at Max-Planck-Institute for Molecular Genetics, and Principal at Odontis Ltd.
He holds a doctorate degree from King's College London.
Tim Allsopp active positions
| Companies | Position | Start |
|---|---|---|
| The University of Edinburgh | Corporate Officer/Principal | 2009-11-19 |
Former positions of Tim Allsopp
| Companies | Position | End |
|---|---|---|
Odontis Ltd.
 Odontis Ltd. Miscellaneous Commercial ServicesCommercial Services Odontis is developing a biological replacement tooth product - the BioToothTM. The research is lead by Professor Paul Sharpe at King's College London Dental Institute. His team has demonstrated that tooth development can be initiated in stem cells, and that fully formed teeth can be created in developmental models. This is pioneering in that it represents one of the very few examples of a fully integrated tissue engineered organ. The technology opens the potential for the implantation of cultured cells in patients to grow and replace damaged or missing teeth. Odontis has attracted over £2 million of funding to date to progress the technology to commercial development. | Corporate Officer/Principal | 2011-01-17 |
| Max-Planck-Institute for Molecular Genetics | Corporate Officer/Principal | - |
| Stem Cell Sciences Plc | Chief Tech/Sci/R&D Officer | - |
Training of Tim Allsopp
| King's College London | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Odontis Ltd.
Odontis Ltd. Miscellaneous Commercial ServicesCommercial Services Odontis is developing a biological replacement tooth product - the BioToothTM. The research is lead by Professor Paul Sharpe at King's College London Dental Institute. His team has demonstrated that tooth development can be initiated in stem cells, and that fully formed teeth can be created in developmental models. This is pioneering in that it represents one of the very few examples of a fully integrated tissue engineered organ. The technology opens the potential for the implantation of cultured cells in patients to grow and replace damaged or missing teeth. Odontis has attracted over £2 million of funding to date to progress the technology to commercial development. | Commercial Services |
| Stem Cell Sciences Plc | Commercial Services |
- Stock Market
- Insiders
- Tim Allsopp
